Start Date
May 30, 2023
Primary Completion Date
November 1, 2023
Study Completion Date
November 1, 2023
Recombinant human IL-7-hyFc (NT-I7)
NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
Vaccine sequence 1
Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
Vaccine sequence 2
Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
National Institutes of Health Clinical Center, Bethesda
Collaborators (1)
NeoImmuneTech
INDUSTRY
National Cancer Institute (NCI)
NIH